expected to produce public benefits that outweigh possible adverse effects.

A particular activity may be found to meet the "closely related to banking" test if it is demonstrated that banks have generally provided the proposed activity; that banks generally provide services that are operationally or functionally similar to the proposed activity so as to equip them particularly well to provide the proposed activity; or that banks generally provide services that are so integrally related to the proposed activity as to require their provision in a specialized form. National Courier Ass'n v. Board of Governors, 516 F.2d 1229, 1237 (D.C. Cir. 1975). In addition, the Board may consider any other basis that may demonstrate that the activity has a reasonable or close relationship to banking or managing or controlling banks. Board Statement Regarding Regulation Y (49 FR 806 (1984)).

The Board has previously approved, by regulation, providing investment and financial advisory services, 12 CFR 225.25(b)(4)(i)-(iv) and (vi)(A)(1) and (2), and providing investment advice to non-affiliated persons with respect to the purchase and sale of financial futures contracts and options on such contracts, 12 CFR 225.25(b)(19). The Board also has previously determined by order that the provision of investment advisory services with respect to financial futures on bonds, interest rate, and stock and bond indices is a permissible activity pursuant to Section 4(c)(8) of the BHC Act. See SR 93-27; National Westminster Bank plc, 78 Federal Reserve Bulletin 953 (1992); Manufacturers Hanover Corporation, 76 Federal Reserve Bulletin 774 (1990); and The HongKong and Shanghai Banking Corporation, 76 Federal Reserve Bulletin 770 (1990). The Board also has approved the providing of investment advice through limited partnerships. See Meridian Bancorp, Inc., 80 Federal Reserve Bulletin 736 (1994). Applicant maintains that Company will conduct its proposed investment advisory activities subject to the requirements and limitations of the Board's Regulation Y and the conditions and limitations of the Board's previous

In order to satisfy the proper incident to banking test, section 4(c)(8) of the BHC Act requires the Board to find that the performance of the activities by Company can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition,

conflicts of interest, or unsound banking practices. Applicant believes that the proposed activities will benefit the public by promoting competition in the delivery of high quality investment management services. Applicant also believes that approval of this application would allow Company to enhance its services to existing clients and provide additional investment advisory services to new clients. Applicant believes that the proposed activities will not result in any unsound banking practices or other adverse effects.

In publishing the proposal for comment, the Board does not take a position on issues raised by the proposal. Notice of the proposal is published solely in order to seek the views of interested persons on the issues presented by the application and does not represent a determination by the Board that the proposal meets, or is likely to meet, the standards of the BHC Act.

Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than August 15, 1995. Any request for a hearing on this application must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

This application may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, July 25, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 95–18693 Filed 7–28–95; 8:45 am] BILLING CODE 6210–01–F

Colfax Bancshares, Inc.; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 95-16899) published on page 35748 of the issue for Tuesday, July 11, 1995.

Under the Federal Reserve Bank of Chicago heading, the entry for Colfax Bancshares, Inc., is revised to read as follows: 1. Dentel Bancorporation, Victor, Iowa; and Colfax Bancshares, Inc., Victor, Iowa, to acquire 100 percent of the voting shares of Maxwell Bancorporation, Maxwell, Iowa, and thereby indirectly acquire Maxwell State Bank, Maxwell, Iowa.

Comments on this application must be received by August 4, 1995.

Board of Governors of the Federal Reserve System, July 25, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 95–18692 Filed 7–28–95; 8:45 am] BILLING CODE 6210–01–F

Ida Grove Bancshares, Inc.; Notice of Application to Engage de novo in Permissible Nonbanking Activities

The company listed in this notice has filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage de novo, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources. decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 15, 1995.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Ida Grove Bancshares, Inc., Ida Grove, Iowa; to engage de novo in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, July 25, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board. [FR Doc. 95–18694 Filed 7–28–95; 8:45 am] BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration on Aging

White House Conference on Aging

AGENCY: White House Conference on Aging, AoA, HHS.

ACTION: Notice of meeting.

SUMMARY: Notice is hereby given, pursuant to Title II of the Older Americans Act Amendments of 1987, Pub. L. 100–175 as amended by Pub. L. 102–375 and Pub. L. 103–171, that the 1995 White House Conference on Aging Advisory Committee on Disabilities will hold a meeting on Thursday, August 10, 1995 from 10 a.m. to 2:30 p.m. More specific information on the location of the meeting can be obtained by calling the telephone number given below.

The meeting of the Committee shall be open to the public. Records shall be kept of all Committee proceedings and will be available for public inspection at 501 School Street, SW, 8th Floor, Washington, DC 20024.

FOR FURTHER INFORMATION CONTACT:

White House Conference on Aging, 501 School Street, SW, 8th Floor, Washington, DC 20024; telephone (202) 245–7116.

Dated: July 25, 1995.

Fernando M. Torres-Gil,

Assistant Secretary for Aging. [FR Doc. 95–18701 Filed 7–28–95; 8:45 am] BILLING CODE 4130–02–M

Food and Drug Administration [Docket No. 95F-0191]

General Electric Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the General Electric Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polyestercarbonate resins produced by the condensation of 4,4'-isopropylidenediphenol, carbonyl chloride, terephthaloyl chloride, and isophthaloyl chloride such that the finished resins are composed of 45 to 85 percent ester of which up to 55 percent is the terephthaloyl isomer, as articles or components of articles in contact with food.

DATES: Written comments on the petitioner's environmental assessment by August 30, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3094.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4470) has been filed by the General Electric Co., One Lexan Lane, Mt. Vernon, IN 47620-9364. The petition proposes to amend the food additive regulations in § 177.1585 Polyestercarbonate resins (21 CFR 177.1585) to provide for the safe use of polyestercarbonate resins produced by the condensation of 4,4'isopropylidenediphenol, carbonyl chloride, terephthaloyl chloride, and isophthaloyl chloride such that the finished resins are composed of 45 to 85 percent ester of which up to 55 percent is the terephthaloyl isomer, as articles or components of articles in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before August 30, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any

comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: July 14, 1995.

George W. Pauli,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–18626 Filed 7–28–95; 8:45 am] BILLING CODE 4160–01–F

[Docket No. 95E-0093]

Determination of Regulatory Review Period for Purposes of Patent Extension; NISOCOR

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for NISOCOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382. SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent

Term Restoration Act (Pub. L. 100–670)

generally provide that a patent may be